Greg Mayes is the founder of Reunion Neuroscience. Reunion Neuroscience has raised $233M in total funding. Latest round: Series A.
Greg Mayes is the President and CEO of Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapeutics. He joined in September 2022 and has since led the company through Phase 1 trials, advanced Phase 2 studies for postpartum depression, and managed the company's transition from public to private.
Full founder directory · Investor directory · Company funding database · Fundraising library